Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 1:00 PM ET on June 6 at the Jefferies Global Healthcare Conference, taking place June 4-6, 2024, in New York City, New York.
馬薩諸塞州沃特敦，2024年5月30日（GLOBE NEWSWIRE）——Werewolf Therapeutics, Inc.（“公司” 或 “狼人”）（納斯達克股票代碼：HOWL）是一家率先開發旨在刺激人體免疫系統以治療癌症的條件激活療法的創新生物製藥公司，今天宣佈，Werewolf總裁兼首席執行官丹尼爾·希克林博士今天宣佈，Werewolf總裁兼首席執行官丹尼爾·希克林博士，Werewolf首席醫學官蘭迪·艾薩克斯醫學博士將於美國東部時間6月6日下午1點在傑富瑞全球醫療保健公司參加爐邊談話會議將於2024年6月4日至6日在紐約州紐約市舉行。
A live webcast link for the Jefferies Global Healthcare Conference event will be available at An archived replay will be available for approximately 90 days following the event.
傑富瑞全球醫療保健大會活動的網絡直播鏈接將在活動結束後約90天內提供存檔重播。
About Werewolf Therapeutics:
關於狼人療法：
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. We are leveraging our proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We expect to advance WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent.
Werewolf Therapeutics, Inc. 是一家創新的生物製藥公司，率先開發旨在刺激人體免疫系統的療法，用於治療癌症和其他免疫介導疾病。我們正在利用我們專有的PREDATOR平台來設計刺激適應性和先天免疫的條件激活分子，目標是解決傳統促炎免疫療法的侷限性。我們的INDUKINE分子旨在在外周組織中保持非活性，但在腫瘤微環境中有選擇地激活。我們最先進的臨床階段候選產品 WTX-124 和 WTX-330 分別是系統輸送、條件激活的白介素-2（IL-2）和白介素-12（IL-12）INDUKINE分子，用於治療實體瘤。我們預計將作爲單一藥物推進多種腫瘤類型的 WTX-124，與免疫檢查點抑制劑聯合使用，在多種腫瘤類型中推進 WTX-330 或作爲單一藥物治療非霍奇金淋巴瘤。
Investor Contact:
Josh Rappaport
Precision AQ
212.362.1200
Josh.Rappaport@precisionaq.com
投資者聯繫人：
喬什·拉帕波特
精度 AQ
212.362.1200
Josh.Rappaport@precisionaq.com
Amanda Sellers
VERGE Scientific Communications
301.332.5574
asellers@vergescientific.com
阿曼達塞爾斯
VERGE 科學通訊
301.332.5574
asellers@vergescientific.com
Company Contact:
Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
elubman@werewolftx.com
公司聯繫人：
艾倫·盧布曼
首席商務官
狼人療法
elubman@werewolftx.com
譯文內容由第三人軟體翻譯。